Study On The Differential Expression Of Anti-vinculin And Anti-cdtB In Spleen And Stomach Weak IBS-D And IBLS

ObjectiveUlcerative colitis(UC)patients presented IBS like symptoms in remission,but no obvious signs of inflammatory reaction were detected.This clinical phenomenon is worth thinking about.UC and IBS are different diseases,but they have common clinical characteristics.So we need to rethink these two diseases.To investigate the differences in the expression of vinculin antibody and cdtB antibody(anti-cytolethal B)in patients with diarrheal irritable bowel syndrome(IBS-D)and Irritable Bowel Syndrome-Like Symptoms(IBLS)and healthy persons.It provides some unique perspectives for the understanding of the pathophysiology of IBS-D and IBLS by biomarkers.It is possible to overlap IBS with remission IBD.Moreover,currently there is no repeatable non-invasive test for the diagnosis of IBS in clinical practice,which increases the diagnostic uncertainty of doctors.Biomarkers are the first time to make the diagnosis of IBS specific rather than "exclude diagnosis".So the aim of this study was based on the results of clinical patients blood ELISA,explore the ability of vinculin antibodies and cdtB antibodies to distinguish between ulcerative colitis Irritable Bowel Syndrome-Like Symptoms and Irritable Bowel Syndrome,To provide more theoretical basis for this two kinds of disease pathogenesis and effective drug treatment.MethodIn this study,from May 2018 to March 2019,the outpatients of Zaijian Wang,Director of the Third Affiliated Hospital of Beijing University of Traditional Chinese Medicine,and Junxiang Li,Director of the Oriental Hospital of Beijing University of Traditional Chinese Medicine,were selected as the patients with irritable bowel syndrome in remission stage of ulcerative colitis with weakness of spleen and stomach,diarrhea irritable bowel syndrome with weakness of spleen and stomach,and health Group.1.Disease activity score,endoscopic score,anxiety and depression score(self-assessment)were performed.2.Blood specimens:check before detection of liver,kidney function,such as routine examination,centrifugal,peripheral blood samples in a timely manner to-80℃,liquid nitrogen tank.3.Antibody levels were determined by enzyme-linked immunosorbent assay(ELISA):the optical density(OD)values were read to compare the levels of the vinculin antibody and cdtB antibody.The original OD value is used for data analysis.4.SPSS20.0 software was used for statistical analysis.The measurement data were expressed as x±s,and the data were first tested for normality and homogeneity of variance.T-test was used for data with normal distribution and homogeneity of variance,and non-parametric test was used for data that did not conform to normal distribution or homogeneity of variance.Test level=0.05.ResultThe level of vinculin antibody was different in the spleen-gastric asthenia IBS-D group and spleen-gastric asthenia IBLS group,and the difference was statistically significant(P<0.05).In addition,the difference was also statistically significant between the IBS-D group and the healthy control group,and between the IBLS group and the healthy control group(P<0.05).There were statistically significant differences in the content of cdtB antibody between the spleen-gastric aseismic IBS-D group and the spleen-gastric aseismic IBLS group(P>0.05),and there were statistically significant differences in the content between the IBS-D group and the healthy group,and between the IBLS group and the healthy group.The sensitivity of the two kinds of antibodies in the identification of IBS-D and IBLS was higher,both of which were95%.In the specificity test,vinculin antibody was found to be higher than cdtB antibody in the identification of patients with IBS-D and IBLS.ConclusionVinculin antibodies and cdtB antibodies in distinguishing between the same TCM syndrome type of ulcerative colitis bowel symptoms with diarrhea type irritable bowel syndrome in a certain sensitivity,and vinculin antibodies can be used as a judgment of ulcerative colitis symptoms of irritable bowel sample remission is special biomarkers of irritable bowel syndrome,cdtB antibodies in distinguishing between IBS-D and IBLS lack specificity,so temporarily do not recommend to distinguish cdtB ulcerative colitis symptoms of irritable bowel sample remission and diarrhea type irritable bowel syndrome.But vinculin antibody in two diseases in the study of the difference of the antibody concentration,its high specificity,can consider to appear as remission differentiate ulcerative colitis bowel symptoms with a biomarker of irritable bowel syndrome,enrich the irritable bowel syndrome in addition to relying on symptom diagnosis and endoscopic diagnosis of diagnostic methods,the detection as a kind of simple and feasible method,and only do blood Elisa as irritable bowel syndrome and ulcerative colitis symptoms of irritable bowel sample remission of these two kinds of disease of a train of thought.It may also have some clinical application value in diagnosis.Anxiety in patients with IBS-D and IBLS found that when the prevalence of depression in patients with IBS-D with IBLS self-evaluation of SAS and SDS scale mean statistically negative gradient,and were higher than normal,but there was no statistically significant difference between them,that state of anxiety or depression in the irritable bowel syndrome patients and irritable bowel syndrome-like symptoms in ulcerative colitis patients in clinical remission with no significant difference.